RLY-2608 clinical trials
RLY-2608 is named as an intervention in 2 current clinical trials in our USA, France, Spain, Italy, Australia, Ireland, UK, Germany and Belgium registers. 2 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Relay Therapeutics, Inc. The most-studied condition is PIK3CA Mutation.
How RLY-2608 works
All drug targets →- Breast cancerPhase 3
- PIK3CA-related overgrowth spectrumPhase 2
- Pik3ca related overgrowth spectrumPhase 2
- CancerPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6068523, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for RLY-2608
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for RLY-2608
- ChEMBL
- CHEMBL6068523
- PubChem CID
- 166822065
- CAS number
- 2733573-94-7
- FDA UNII
- LR5XLA3BPC
- Wikidata
- Q140529380
- Wikipedia
- Zovegalisib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of RLY-2608
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
NCT06789913 · PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations
|
Phase 2 | Recruiting | Relay Therapeutics, Inc | Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Australia |
|
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432 · PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer
|
Phase 1 | Recruiting | Relay Therapeutics, Inc | USA, France, Spain, Italy, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with RLY-2608
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Relay Therapeutics, Inc | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about RLY-2608 trials
How many clinical trials are testing RLY-2608?
2 current trials in our USA, France, Spain, Italy, Australia, Ireland, UK, Germany and Belgium registers name RLY-2608 as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are RLY-2608 trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Australia, 1 with sites in Ireland, 1 with sites in UK, 1 with sites in Germany and 1 with sites in Belgium. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors RLY-2608 clinical trials?
The lead sponsor is Relay Therapeutics, Inc. The number in brackets is how many trials each organisation leads.
Are there RLY-2608 clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RLY-2608 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RLY-2608 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RLY-2608 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.